Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mirabegron in pediatric NDO (Crocodile)
NCT02751931Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2016
- Primary completion
- Nov 2018
- Modality
- Small Molecules
- Countries
- 19
01
Overview
Phase 3, open-label trial of mirabegron in neurogenic detrusor overactivity (NDO) (2 arms), sponsored by Astellas Pharma. Primary endpoint: Change From Baseline in Maximum Cystometric Capacity at 24 weeks. Started Jun 2016; status: completed.
02
Drugs
mirabegron
03
Conditions
neurogenic detrusor overactivity (NDO)
Beyond the preview
Go deeper on NCT02751931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02751931.